Business
Establishment Labs Announces Independent Publication Detailing New Advancements in Hybrid Breast Reconstruction Technique Using Motiva Ergonomix Implants
SANTA BARBARA, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s
About this update from Establishment Labs Holdings Inc.
[{"type":"text","content":"SANTA BARBARA, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced today that a recently published independent study concluded that the hybrid breast reconstruction approach using Motiva® Ergonomix implants improved outcomes in implant-based breast reconstructions.\n Published in Plastic and Reconstructive Surgery-Global Open, this independent study analyzed 56 prepectoral, hybrid breast reconstructions in 33 patients performed between 2014 to 2017. Utilizing the two-step, prepectoral reconstruction approach, the study found that Motiva Ergonomix implants allowed better control of the final breast shape, and complications related to submuscular approaches were avoided. The study further noted that Motiva Ergonomix implants “offer a wide set of advantages related to their surface features that can benefit short- and long-term adverse events related to chronic inflammation and fibrotic reaction.” “The introduction of ergonomic implants that adapt to the position and motion of the breast is a new advancement in hybrid breast reconstruction surgery that improves patient outcomes over the traditional choice of anatomical and round implants,” said study co-author Filip B. J. L. Stillaert, Assistant Professor of Plastic and Reconstructive Surgery at the Ghent University Hospital in Belgium. “The viscoelastic properties of the Motiva Ergonomix breast implant allow it to adapt better to gravitational force and mimic natural movement. Overall, patients were very satisfied with the clinical outcome and the natural touch of the breast.” “Based on our success in breast augmentation, Establishment Labs is committed to introducing safe, innovative technologies that fundamentally improve aesthetic outcomes in breast reconstruction, especially for younger women who have suffered from breast cancer,” said chief executive officer Juan José Chacón-Quirós. “We are thrilled to see the aesthetic results of this independent study using our Motiva Ergonomix implants in hybrid breast reconstruction. We believe the use of our Ergonomix implants, alongside our Motiva Flora tissue expander, the only MRI-compatible tissue expander with an integrated valve, will be a tremendous advancement for ...